const g=(e="")=>e==="definition"?i():e==="prevalence"?t():e==="pathogenesis"?n():e==="pathophysiology"?a():e==="pathology"?o():e==="types-classification"?s():e==="monitoring"?r():e==="investigations"?l():e==="management"?c():e==="clinical-outcomes"?p():e==="complications"?m():e==="prevention"?d():e==="kenya-context"?u():[{title:"Fetal Growth Restriction (FGR) - Comprehensive Management",clickableItems:[{text:"ğŸ“– Definition & Terminology",sectionId:"definition"},{text:"ğŸ“Š Prevalence & Epidemiology",sectionId:"prevalence"},{text:"ğŸ§¬ Pathogenesis",sectionId:"pathogenesis"},{text:"âš¡ Pathophysiology",sectionId:"pathophysiology"},{text:"ğŸ”¬ Pathology & Placental Changes",sectionId:"pathology"},{text:"ğŸ“‹ Types & Classification",sectionId:"types-classification"},{text:"ğŸ“± Monitoring & Surveillance",sectionId:"monitoring"},{text:"ğŸ” Investigations & Diagnosis",sectionId:"investigations"},{text:"ğŸ’Š Management Strategies",sectionId:"management"},{text:"ğŸ“ˆ Clinical Outcomes",sectionId:"clinical-outcomes"},{text:"âš ï¸ Complications",sectionId:"complications"},{text:"ğŸ›¡ï¸ Prevention Strategies",sectionId:"prevention"},{text:"ğŸ‡°ğŸ‡ª Kenya-Specific Considerations",sectionId:"kenya-context"}]},{title:"Fetal Growth Restriction Overview",points:["ğŸ“Š **Global Impact**: Affects 3-9% of pregnancies worldwide","ğŸ¯ **Clinical Significance**: Major cause of perinatal morbidity and mortality","âš¡ **Risk Factors**: Maternal, fetal, placental, and environmental factors","ğŸ”„ **Classification**: Early vs late onset, symmetric vs asymmetric","ğŸ” **Diagnosis**: EFW or AC <10th percentile with additional criteria","ğŸ“± **Monitoring**: Serial growth scans, Doppler studies, biophysical assessment","ğŸ¤° **Management**: Maternal optimization, fetal surveillance, timing of delivery"]},{title:"Key Clinical Points",subsections:[{title:"Diagnostic Criteria",points:["ğŸ“ **Size Criteria**: EFW <10th percentile for gestational age","ğŸ“‰ **Growth Velocity**: Crossing percentiles downward","ğŸŒŠ **Doppler Changes**: Abnormal umbilical artery Doppler","ğŸ’§ **Oligohydramnios**: Reduced amniotic fluid volume"]},{title:"Risk Stratification",points:["ğŸ”´ **High Risk**: Early onset, severe Doppler changes","ğŸŸ¡ **Moderate Risk**: Late onset, mild Doppler changes","ğŸŸ¢ **Low Risk**: Isolated small size, normal Doppler","âš¡ **Emergency**: Absent/reversed end-diastolic flow"]},{title:"Management Priorities",points:["ğŸ¯ **Optimize Maternal Health**: Treat underlying conditions","ğŸ“± **Intensive Monitoring**: Frequent assessments","âš–ï¸ **Balance Risks**: Prematurity vs continued intrauterine growth","ğŸ¥ **Delivery Planning**: Timing, mode, neonatal preparation"]}]}],i=()=>[{title:"Definition and Terminology of Fetal Growth Restriction",subsections:[{title:"Current Definitions",points:["ğŸ“ **FGR Definition**: Failure of fetus to reach genetic growth potential","ğŸ“Š **Statistical Definition**: EFW <10th percentile for gestational age","âš¡ **Functional Definition**: Pathological process affecting fetal growth","ğŸ”„ **Dynamic Definition**: Decrease in growth velocity over time","ğŸ¯ **Clinical Definition**: Small fetus with evidence of placental insufficiency","ğŸ§¬ **Biological Definition**: Inadequate nutrient and oxygen delivery"]},{title:"Terminology Evolution",points:["ğŸ“– **Historical Terms**: Intrauterine growth retardation (IUGR)","ğŸ”„ **Current Preference**: Fetal Growth Restriction (FGR)","âš¡ **Rationale**: Less stigmatizing, more accurate description","ğŸ¯ **International Usage**: FGR adopted by major societies","ğŸ“Š **Clinical Distinction**: FGR vs Small for Gestational Age (SGA)","ğŸ§¬ **Pathophysiological Focus**: Emphasis on underlying pathology"]},{title:"Diagnostic Criteria",points:["ğŸ“ **Primary Criterion**: EFW <10th percentile","ğŸ“‰ **Secondary Criteria**: Abnormal Doppler studies","ğŸ’§ **Associated Features**: Oligohydramnios","ğŸ”„ **Growth Pattern**: Crossing percentiles downward","âš¡ **Severity Markers**: <3rd percentile, absent end-diastolic flow","ğŸ¯ **Composite Assessment**: Multiple parameters combined"]},{title:"Classification Systems",points:["â° **Timing**: Early onset (<32 weeks) vs Late onset (â‰¥32 weeks)","ğŸ“Š **Severity**: Mild (<10th), Moderate (<5th), Severe (<3rd percentile)","ğŸ”„ **Growth Pattern**: Symmetric vs Asymmetric growth restriction","ğŸŒŠ **Doppler Status**: Normal vs Abnormal umbilical artery Doppler","ğŸ’§ **Fluid Status**: With or without oligohydramnios","ğŸ§¬ **Etiology**: Placental vs fetal vs maternal causes"]},{title:"Related Terminology",points:["ğŸ“Š **Small for Gestational Age (SGA)**: Birth weight <10th percentile","âš¡ **Low Birth Weight (LBW)**: Birth weight <2500g","ğŸ¯ **Very Low Birth Weight (VLBW)**: Birth weight <1500g","ğŸ’« **Extremely Low Birth Weight (ELBW)**: Birth weight <1000g","ğŸ”„ **Appropriate for Gestational Age (AGA)**: 10th-90th percentile","ğŸ“ **Large for Gestational Age (LGA)**: >90th percentile"]}]}],t=()=>[{title:"Prevalence and Epidemiology of Fetal Growth Restriction",subsections:[{title:"Global Prevalence",points:["ğŸŒ **Worldwide**: 3-9% of all pregnancies","ğŸ­ **Developed Countries**: 3-5% prevalence","ğŸŒ¾ **Developing Countries**: 6-30% prevalence","ğŸ“Š **Population Variation**: Ethnic and racial differences","ğŸ’° **Socioeconomic Factors**: Higher in low-income populations","ğŸ”„ **Temporal Trends**: Varying trends over time"]},{title:"Regional Variations",points:["ğŸ‡ºğŸ‡¸ **United States**: 3-7% of births","ğŸ‡ªğŸ‡º **Europe**: 2-8% regional variation","ğŸŒ **Asia**: 5-15% with country-specific differences","ğŸŒ **Sub-Saharan Africa**: 10-25% in some regions","ğŸ‡®ğŸ‡³ **South Asia**: 15-30% in certain populations","ğŸŒ **Latin America**: 5-15% regional variation"]},{title:"Risk Factor Epidemiology",points:["ğŸ‘© **Maternal Age**: Increased risk <18 or >35 years","ğŸ¤° **Parity**: Nulliparity and grand multiparity","âš–ï¸ **Maternal BMI**: Both underweight and obesity","ğŸš¬ **Smoking**: 2-3 fold increased risk","ğŸ· **Alcohol**: Dose-dependent relationship","ğŸ’Š **Drug Use**: Cocaine, heroin associated risks"]},{title:"Medical Conditions",points:["ğŸ’“ **Hypertensive Disorders**: 20-25% of FGR cases","ğŸ¯ **Diabetes**: Both pre-gestational and gestational","ğŸ« **Chronic Disease**: Renal, cardiac, respiratory conditions","ğŸ§¬ **Genetic Factors**: Maternal and fetal chromosomal abnormalities","ğŸ¦  **Infections**: TORCH infections, malaria","âš•ï¸ **Autoimmune Disorders**: SLE, antiphospholipid syndrome"]},{title:"Placental Factors",points:["ğŸŒŠ **Placental Insufficiency**: 60-70% of FGR cases","ğŸ’« **Placental Abnormalities**: Structural and functional defects","ğŸ©¸ **Vascular Pathology**: Decidual vasculopathy","ğŸ”„ **Placental Infarction**: Thrombosis and ischemia","ğŸ“ **Placental Size**: Small placenta association","ğŸ§¬ **Genetic Placental Factors**: Imprinting disorders"]},{title:"Temporal Patterns",points:["â° **Early Onset**: 20-30% of FGR cases (<32 weeks)","ğŸ“… **Late Onset**: 70-80% of FGR cases (â‰¥32 weeks)","ğŸ”„ **Seasonal Variation**: Some geographical regions","ğŸ“ˆ **Trends Over Time**: Improving detection, changing risk factors","ğŸ¯ **Gestational Age Distribution**: Peak incidence timing","ğŸ“Š **Recurrence Risk**: 10-20% in subsequent pregnancies"]}]}],n=()=>[{title:"Pathogenesis of Fetal Growth Restriction",subsections:[{title:"Placental Development Abnormalities",points:["ğŸŒ± **Implantation Defects**: Shallow trophoblast invasion","ğŸ©¸ **Spiral Artery Remodeling**: Incomplete physiological transformation","ğŸ’« **Villous Development**: Abnormal branching angiogenesis","ğŸ”„ **Syncytiotrophoblast Function**: Impaired hormone and transport function","âš¡ **Placental Bed**: Inadequate vascular remodeling","ğŸ§¬ **Genetic Factors**: Placental gene expression alterations"]},{title:"Maternal Vascular Factors",points:["ğŸ’“ **Uterine Blood Flow**: Reduced maternal perfusion","ğŸ©¸ **Spiral Arteries**: Failed transformation to low-resistance vessels","âš¡ **Endothelial Dysfunction**: Impaired vasodilation capacity","ğŸ”„ **Thrombophilia**: Increased thrombotic tendency","ğŸ’« **Hypertensive Disease**: Chronic or pregnancy-induced hypertension","ğŸŒŠ **Autoimmune Disorders**: Antiphospholipid syndrome, SLE"]},{title:"Fetal Factors",points:["ğŸ§¬ **Chromosomal Abnormalities**: Trisomies, sex chromosome abnormalities","ğŸ’« **Genetic Syndromes**: Single gene disorders","ğŸ¦  **Congenital Infections**: TORCH complex, malaria","ğŸ’“ **Cardiac Anomalies**: Structural heart defects","ğŸ§  **Central Nervous System**: Neural tube defects, brain malformations","ğŸ”„ **Multiple Pregnancy**: Twin-to-twin transfusion syndrome"]},{title:"Environmental and Lifestyle Factors",points:["ğŸš¬ **Tobacco Exposure**: Nicotine effects on placental vasculature","ğŸ· **Alcohol Consumption**: Direct fetal toxicity","ğŸ’Š **Drug Use**: Cocaine, opiates, other substances","ğŸŒ¡ï¸ **Environmental Toxins**: Heavy metals, pesticides","ğŸ”ï¸ **High Altitude**: Chronic hypoxia effects","ğŸ½ï¸ **Malnutrition**: Protein-energy malnutrition"]},{title:"Molecular Mechanisms",points:["ğŸ§¬ **Growth Factors**: IGF system dysregulation","âš¡ **Oxidative Stress**: Increased reactive oxygen species","ğŸ”„ **Inflammation**: Chronic inflammatory state","ğŸ’« **Epigenetic Changes**: DNA methylation, histone modifications","ğŸŒŠ **Angiogenic Factors**: VEGF, PlGF, sFlt-1 imbalance","ğŸ¯ **Nutrient Transport**: Placental transport dysfunction"]},{title:"Multifactorial Interactions",points:["ğŸ”„ **Gene-Environment**: Genetic susceptibility and environmental triggers","ğŸ’« **Maternal-Fetal**: Competing metabolic demands","âš¡ **Placental-Fetal**: Transport capacity vs fetal requirements","ğŸŒŠ **Vascular-Metabolic**: Blood flow and nutrient delivery","ğŸ§¬ **Epigenetic Programming**: Long-term developmental consequences","ğŸ¯ **Adaptive Responses**: Fetal adaptation to suboptimal environment"]}]}],a=()=>[{title:"Pathophysiology of Fetal Growth Restriction",subsections:[{title:"Placental Blood Flow Changes",points:["ğŸ©¸ **Reduced Uteroplacental Flow**: Decreased maternal blood supply","âš¡ **Increased Resistance**: Elevated umbilical artery resistance","ğŸ’« **Redistribution**: Preferential flow to vital organs","ğŸ”„ **Autoregulation**: Compensatory mechanisms","ğŸŒŠ **Hypoxemia**: Chronic fetal hypoxia","ğŸ“‰ **Progressive Deterioration**: Worsening flow patterns"]},{title:"Fetal Cardiovascular Adaptations",points:["ğŸ’“ **Cardiac Output**: Redistribution to brain, heart, adrenals","ğŸ§  **Brain Sparing**: Increased middle cerebral artery flow","ğŸ«˜ **Renal Changes**: Decreased renal blood flow","ğŸ« **Pulmonary Flow**: Altered pulmonary circulation","âš¡ **Venous System**: Abnormal venous Doppler patterns","ğŸ”„ **Heart Rate**: Decreased variability, late decelerations"]},{title:"Metabolic Adaptations",points:["ğŸ¯ **Glucose Metabolism**: Altered glucose utilization","ğŸ§¬ **Protein Synthesis**: Reduced anabolic processes","ğŸ’§ **Fluid Balance**: Oligohydramnios development","âš¡ **Oxygen Consumption**: Reduced metabolic rate","ğŸ”„ **Hormone Changes**: Altered growth hormone axis","ğŸ’« **Cellular Energy**: Mitochondrial dysfunction"]},{title:"Placental Transport Dysfunction",points:["ğŸ¯ **Nutrient Transfer**: Impaired amino acid transport","ğŸ’§ **Water Transport**: Altered fluid exchange","âš¡ **Oxygen Transfer**: Reduced oxygen delivery","ğŸ”„ **Waste Removal**: Impaired metabolite clearance","ğŸ’« **Hormone Transport**: Altered endocrine function","ğŸ§¬ **Immunological**: Changed immune transfer"]},{title:"Fetal Organ System Effects",points:["ğŸ§  **Central Nervous System**: Altered brain development","ğŸ’“ **Cardiovascular**: Cardiac remodeling","ğŸ« **Pulmonary**: Lung maturation effects","ğŸ«˜ **Renal**: Nephron development changes","ğŸ½ï¸ **Gastrointestinal**: Gut development alterations","ğŸ¦´ **Musculoskeletal**: Reduced muscle mass"]},{title:"Adaptive vs Maladaptive Responses",points:["âœ… **Adaptive**: Brain sparing, reduced growth rate","âŒ **Maladaptive**: Organ dysfunction, acidosis","âš–ï¸ **Balance**: Short-term survival vs long-term health","ğŸ”„ **Threshold Effects**: When adaptation fails","âš¡ **Critical Periods**: Vulnerable developmental windows","ğŸ¯ **Individual Variation**: Genetic and environmental factors"]}]}],o=()=>[{title:"Pathology and Placental Changes in FGR",subsections:[{title:"Gross Placental Pathology",points:["âš–ï¸ **Placental Weight**: Reduced placental weight (<10th percentile)","ğŸ“ **Size**: Small placental size relative to gestational age","ğŸ”„ **Shape**: Irregular shape, marginal insertion","ğŸ’« **Color Changes**: Pale appearance, infarctions","ğŸ©¸ **Hemorrhage**: Retroplacental hematoma","ğŸ§Š **Calcifications**: Premature calcification"]},{title:"Microscopic Placental Changes",points:["ğŸŒ¿ **Villous Architecture**: Reduced branching angiogenesis","ğŸ©¸ **Vascular Changes**: Obliterative arteriopathy","ğŸ’« **Syncytial Knots**: Increased syncytial knotting","ğŸ”„ **Fibrinoid Deposition**: Excessive fibrinoid","âš¡ **Inflammatory Changes**: Chronic villitis","ğŸ§¬ **Cellular Changes**: Trophoblast apoptosis"]},{title:"Maternal Vascular Pathology",points:["ğŸ©¸ **Spiral Arteries**: Failed physiological transformation","ğŸ’« **Decidual Vasculopathy**: Acute atherosis","âš¡ **Thrombosis**: Maternal vessel thrombosis","ğŸ”„ **Atherosclerosis**: Premature atherosclerotic changes","ğŸŒŠ **Endothelial Changes**: Endothelial dysfunction","ğŸ¯ **Inflammatory Infiltrate**: Chronic inflammation"]},{title:"Fetal Vascular Pathology",points:["ğŸ©¸ **Umbilical Vessels**: Arterial medial hypertrophy","ğŸ’« **Chorionic Vessels**: Thrombosis, obliteration","âš¡ **Capillary Changes**: Reduced capillary density","ğŸ”„ **Angiogenesis**: Impaired new vessel formation","ğŸŒŠ **Vessel Wall**: Smooth muscle hyperplasia","ğŸ§¬ **Endothelial Function**: Altered NO production"]},{title:"Placental Bed Pathology",points:["ğŸ  **Implantation Site**: Shallow trophoblast invasion","ğŸ©¸ **Spiral Artery**: Incomplete remodeling","ğŸ’« **Decidual**: Chronic deciduitis","âš¡ **Myometrial**: Reduced myometrial invasion","ğŸ”„ **Immune Cells**: Altered NK cell function","ğŸŒŠ **Extracellular Matrix**: Matrix remodeling defects"]},{title:"Associated Pathological Findings",points:["ğŸ§Š **Infarctions**: Multiple placental infarcts","ğŸ©¸ **Abruption**: Chronic abruption","ğŸ’« **Chorioamnionitis**: Inflammatory changes","âš¡ **Cord Abnormalities**: Single umbilical artery","ğŸ”„ **Membrane Changes**: Amnion nodosum","ğŸŒŠ **Amniotic Fluid**: Oligohydramnios changes"]}]}],s=()=>[{title:"Types and Classification of Fetal Growth Restriction",subsections:[{title:"Timing-Based Classification",points:["â° **Early Onset FGR**: Diagnosis <32 weeks gestation","ğŸ“… **Late Onset FGR**: Diagnosis â‰¥32 weeks gestation","ğŸ”„ **Very Early**: <24 weeks (often genetic/structural)","ğŸ’« **Early**: 24-32 weeks (typically placental)","ğŸ“ˆ **Late**: 32-37 weeks (maternal factors common)","ğŸ¯ **Term**: â‰¥37 weeks (constitutional vs pathological)"]},{title:"Growth Pattern Classification",points:["âš–ï¸ **Symmetric FGR**: Proportional reduction in all parameters","ğŸ“ **Asymmetric FGR**: Preserved head growth, reduced abdominal growth","ğŸ§  **Head-Sparing**: Normal HC, reduced AC and EFW","ğŸ’« **Mixed Pattern**: Elements of both symmetric and asymmetric","ğŸ”„ **Progressive**: Worsening growth over time","ğŸ“Š **Static**: Stable small size without progression"]},{title:"Severity Classification",points:["ğŸŸ¢ **Mild FGR**: EFW 3rd-10th percentile","ğŸŸ¡ **Moderate FGR**: EFW 1st-3rd percentile","ğŸ”´ **Severe FGR**: EFW <1st percentile","âš¡ **Critical**: Absent/reversed end-diastolic flow","ğŸš¨ **Extreme**: Multiple organ dysfunction","ğŸ’” **Lethal**: Incompatible with survival"]},{title:"Etiology-Based Classification",points:["ğŸ¤° **Maternal Causes**: Hypertension, diabetes, malnutrition","ğŸŒŠ **Placental Causes**: Placental insufficiency, abruption","ğŸ‘¶ **Fetal Causes**: Chromosomal, genetic, infectious","ğŸ”„ **Multifactorial**: Multiple contributing factors","â“ **Idiopathic**: Unknown cause (20-30% of cases)","ğŸ§¬ **Constitutional**: Normal small fetus"]},{title:"Doppler-Based Classification",points:["âœ… **Normal Doppler**: Normal umbilical artery waveforms","ğŸ“ˆ **Increased Resistance**: Elevated pulsatility index","âš ï¸ **Absent End-Diastolic Flow**: AEDF in umbilical artery","ğŸ”´ **Reversed End-Diastolic Flow**: REDF in umbilical artery","ğŸ§  **Brain Sparing**: Reduced MCA pulsatility index","ğŸ’“ **Venous Changes**: Abnormal ductus venosus Doppler"]},{title:"Clinical Classification Systems",points:["ğŸ“Š **Percentile-Based**: <10th, <5th, <3rd percentile","ğŸ“ **Z-Score Based**: Standard deviations below mean","ğŸ¯ **Composite Scores**: Multiple parameter assessment","âš¡ **Risk Stratification**: Low, moderate, high risk","ğŸ”„ **Dynamic Classification**: Changes with monitoring","ğŸ¥ **Management-Based**: Expectant vs immediate delivery"]}]}],r=()=>[{title:"Monitoring and Surveillance in FGR",subsections:[{title:"Growth Assessment",points:["ğŸ“ **Serial Biometry**: EFW measurements every 2-4 weeks","ğŸ“Š **Growth Velocity**: Rate of growth over time","ğŸ¯ **Percentile Tracking**: Crossing percentiles assessment","ğŸ”„ **Customized Charts**: Population-specific growth curves","ğŸ’« **AC Measurement**: Most sensitive parameter for FGR","ğŸ“ˆ **Growth Trajectory**: Plotting growth over time"]},{title:"Doppler Studies",points:["ğŸ©¸ **Umbilical Artery**: Primary screening tool","ğŸ§  **Middle Cerebral Artery**: Brain sparing assessment","ğŸ’“ **Ductus Venosus**: Late-stage cardiovascular changes","ğŸ”„ **Cerebroplacental Ratio**: MCA PI/UA PI ratio","âš¡ **Uterine Arteries**: Maternal vascular assessment","ğŸŒŠ **Venous System**: IVC, UV pulsations"]},{title:"Biophysical Assessment",points:["ğŸ‘¶ **Biophysical Profile**: 5-component assessment","ğŸ’“ **Non-Stress Test**: Fetal heart rate reactivity","ğŸŒŠ **Amniotic Fluid**: AFI or SDP measurement","ğŸ¤² **Fetal Movements**: Maternal perception and visualization","ğŸ« **Breathing Movements**: Fetal breathing assessment","ğŸ’ª **Fetal Tone**: Flexion/extension movements"]},{title:"Cardiotocography",points:["ğŸ“Š **Baseline FHR**: Normal range 110-160 bpm","âš¡ **Variability**: Beat-to-beat variation assessment","ğŸ“ˆ **Accelerations**: Reactive vs non-reactive patterns","ğŸ“‰ **Decelerations**: Late, variable, prolonged","ğŸ”„ **Pattern Recognition**: Sinusoidal, saltatory patterns","â° **Monitoring Frequency**: Based on severity and gestation"]},{title:"Maternal Assessment",points:["ğŸ©¸ **Blood Pressure**: Regular monitoring for hypertension","ğŸ§ª **Laboratory Tests**: Complete blood count, liver function","ğŸ’§ **Proteinuria**: Urine protein assessment","âš–ï¸ **Weight Gain**: Maternal weight monitoring","ğŸ©º **Symptoms**: Headache, visual changes, epigastric pain","ğŸ’Š **Medication Compliance**: Antihypertensive medications"]},{title:"Timing and Frequency",points:["ğŸ“… **Initial Diagnosis**: Comprehensive assessment","ğŸ”„ **Follow-up Intervals**: Based on severity and gestational age","âš¡ **Intensive Monitoring**: Weekly or bi-weekly assessments","ğŸš¨ **Emergency Assessment**: Immediate evaluation for concerning signs","ğŸ“Š **Documentation**: Detailed records of all assessments","ğŸ¯ **Delivery Timing**: Based on monitoring results"]}]}],l=()=>[{title:"Investigations and Diagnosis in FGR",subsections:[{title:"Ultrasound Assessment",points:["ğŸ“ **Biometric Parameters**: BPD, HC, AC, FL measurements","âš–ï¸ **Estimated Fetal Weight**: Using multiple formulas","ğŸ’§ **Amniotic Fluid**: AFI or single deepest pocket","ğŸ«€ **Anatomy Scan**: Detailed structural assessment","ğŸ”„ **Growth Charts**: Plotting on appropriate percentiles","ğŸ“Š **Serial Measurements**: Tracking growth velocity"]},{title:"Doppler Studies Protocol",points:["ğŸ©¸ **Umbilical Artery**: Pulsatility index, resistance index","ğŸ§  **Middle Cerebral Artery**: Peak systolic velocity, PI","ğŸ’“ **Ductus Venosus**: PIV, S/A ratio, A-wave","ğŸ”„ **Cerebroplacental Ratio**: MCA PI/UA PI","âš¡ **Uterine Arteries**: Bilateral assessment, notching","ğŸŒŠ **Additional Vessels**: IVC, hepatic veins if indicated"]},{title:"Maternal Investigations",points:["ğŸ©¸ **Complete Blood Count**: Hemoglobin, platelets","ğŸ§ª **Biochemistry**: Liver function, renal function","ğŸ’§ **Urinalysis**: Protein, microscopy","ğŸ¦  **Infectious Screen**: TORCH, syphilis, malaria","ğŸ§¬ **Autoimmune**: ANA, anti-Ro/La, lupus anticoagulant","ğŸ¯ **Glucose Tolerance**: Diabetes screening"]},{title:"Fetal Investigations",points:["ğŸ§¬ **Genetic Testing**: Amniocentesis, CVS if indicated","ğŸ¦  **Infection Screen**: Amniocentesis for TORCH","ğŸ’“ **Fetal Echocardiography**: If structural anomalies","ğŸ§  **Neurosonography**: CNS assessment","ğŸ”¬ **Cordocentesis**: Rarely performed, specific indications","ğŸ“Š **Karyotype**: Chromosomal analysis"]},{title:"Specialized Investigations",points:["ğŸ©¸ **Thrombophilia Screen**: If recurrent FGR","ğŸ’« **Placental Studies**: If delivery occurs","ğŸ§¬ **Genetic Counseling**: Family history, consanguinity","ğŸ“· **MRI**: If complex structural anomalies","ğŸ”¬ **Amino Acid Analysis**: Metabolic disorders","ğŸ§ª **Hormonal Assessment**: Thyroid, cortisol"]},{title:"Diagnostic Algorithms",points:["ğŸ“Š **Risk Assessment**: Initial screening and stratification","ğŸ”„ **Stepwise Approach**: Systematic investigation protocol","âš¡ **Urgent vs Routine**: Prioritizing investigations","ğŸ¯ **Cost-Effectiveness**: Resource allocation","ğŸ“š **Evidence-Based**: Following established guidelines","ğŸ¥ **Multidisciplinary**: Involving appropriate specialists"]}]}],c=()=>[{title:"Management Strategies for Fetal Growth Restriction",subsections:[{title:"General Management Principles",points:["ğŸ¯ **Optimize Maternal Health**: Treat underlying conditions","ğŸ“Š **Risk Stratification**: Categorize severity and urgency","âš–ï¸ **Balance Risks**: Prematurity vs continued intrauterine risk","ğŸ”„ **Individualized Care**: Patient-specific management plans","ğŸ‘¥ **Multidisciplinary Team**: Maternal-fetal medicine, neonatology","ğŸ“š **Evidence-Based**: Following established guidelines"]},{title:"Maternal Optimization",points:["ğŸ’Š **Antihypertensive Therapy**: For chronic or pregnancy hypertension","ğŸ½ï¸ **Nutritional Support**: Adequate caloric and protein intake","ğŸš« **Smoking Cessation**: Immediate and complete cessation","ğŸ’§ **Hydration**: Adequate fluid intake","ğŸ›ï¸ **Rest**: Modified activity, lateral positioning","ğŸ’Š **Aspirin**: Low-dose if indicated for preeclampsia prevention"]},{title:"Expectant Management",points:["ğŸ“± **Intensive Monitoring**: Frequent fetal surveillance","ğŸ¥ **Outpatient vs Inpatient**: Based on severity and compliance","ğŸ“Š **Serial Assessment**: Regular growth and Doppler studies","âš¡ **Delivery Planning**: Preparing for various scenarios","ğŸš¨ **Emergency Protocols**: Clear criteria for immediate delivery","ğŸ“š **Patient Education**: Warning signs, when to seek care"]},{title:"Timing of Delivery",points:["â° **Gestational Age**: Balancing maturity vs intrauterine risk","ğŸ“Š **Severity Assessment**: Doppler studies, biophysical profile","ğŸ”´ **Immediate Delivery**: REDF, abnormal DV, non-reassuring CTG","ğŸŸ¡ **Planned Delivery**: AEDF, oligohydramnios, growth cessation","ğŸŸ¢ **Expectant Management**: Normal Doppler, reassuring surveillance","ğŸ¯ **Individualized Timing**: Patient-specific factors"]},{title:"Mode of Delivery",points:["ğŸšª **Vaginal Delivery**: If fetal status allows and no contraindications","ğŸ”ª **Cesarean Section**: Fetal distress, breech presentation","âš¡ **Emergency Cesarean**: Acute fetal compromise","ğŸ¯ **Planned Cesarean**: Severe FGR, previous cesarean","ğŸ“Š **Continuous Monitoring**: Intensive intrapartum surveillance","ğŸ‘¶ **Neonatal Team**: Pediatric team presence at delivery"]},{title:"Interventions of Uncertain Benefit",points:["ğŸ’Š **Sildenafil**: Limited evidence, research ongoing","ğŸŒŠ **Maternal Oxygenation**: No proven benefit","ğŸ’§ **Bed Rest**: May cause maternal complications","ğŸ½ï¸ **Specific Diets**: Limited evidence for benefit","ğŸ’Š **Vitamins/Supplements**: Beyond standard prenatal vitamins","ğŸ”„ **Alternative Therapies**: Acupuncture, massage"]}]}],p=()=>[{title:"Clinical Outcomes in Fetal Growth Restriction",subsections:[{title:"Immediate Neonatal Outcomes",points:["âš–ï¸ **Low Birth Weight**: Increased risk of complications","ğŸ« **Respiratory Distress**: Higher incidence of RDS","ğŸŒ¡ï¸ **Temperature Instability**: Poor thermoregulation","ğŸ¯ **Hypoglycemia**: Reduced glycogen stores","ğŸ©¸ **Polycythemia**: Compensatory response to hypoxia","ğŸ§  **Neurological Issues**: HIE, intraventricular hemorrhage"]},{title:"Short-term Complications",points:["ğŸ¼ **Feeding Difficulties**: Poor suck, gastric intolerance","ğŸ“ˆ **Growth Failure**: Postnatal growth restriction","ğŸ¦  **Infection Risk**: Increased susceptibility","ğŸ’” **Cardiac Issues**: Pulmonary hypertension","ğŸ«˜ **Renal Problems**: Acute kidney injury","ğŸ§  **Neurodevelopmental**: Early delays"]},{title:"Long-term Childhood Outcomes",points:["ğŸ“š **Cognitive Development**: Learning difficulties, lower IQ","ğŸƒ **Physical Growth**: Continued growth restriction","ğŸ§  **Neurodevelopment**: ADHD, autism spectrum disorders","ğŸ’ª **Motor Development**: Gross and fine motor delays","ğŸ¯ **Behavioral Issues**: Attention problems, hyperactivity","ğŸ« **School Performance**: Academic challenges"]},{title:"Adult Health Consequences",points:["ğŸ’“ **Cardiovascular Disease**: Hypertension, coronary artery disease","ğŸ¯ **Metabolic Syndrome**: Diabetes, obesity, dyslipidemia","ğŸ§  **Neurological**: Increased stroke risk","ğŸ« **Respiratory**: Reduced lung function","ğŸ«˜ **Renal Disease**: Chronic kidney disease","ğŸ§¬ **Reproductive**: Subfertility, pregnancy complications"]},{title:"Intergenerational Effects",points:["ğŸ¤° **Pregnancy Complications**: Higher risk in offspring","ğŸ‘¶ **Fetal Growth**: Increased FGR risk in next generation","ğŸ§¬ **Epigenetic Changes**: Transgenerational programming","ğŸ’“ **Cardiovascular Risk**: Inherited predisposition","ğŸ¯ **Metabolic Programming**: Altered metabolism","ğŸ”„ **Cycle Perpetuation**: Breaking the cycle challenges"]},{title:"Factors Affecting Outcomes",points:["â° **Gestational Age**: Earlier onset worse outcomes","ğŸ“Š **Severity**: More severe restriction worse prognosis","ğŸ”„ **Type**: Symmetric worse than asymmetric","ğŸ§¬ **Etiology**: Genetic causes worse outcomes","ğŸ¥ **Neonatal Care**: Quality of immediate care","ğŸ‘¥ **Social Factors**: Socioeconomic status, family support"]}]}],m=()=>[{title:"Complications of Fetal Growth Restriction",subsections:[{title:"Antepartum Complications",points:["ğŸ’€ **Stillbirth**: 5-10 fold increased risk","ğŸ’§ **Oligohydramnios**: Reduced amniotic fluid volume","ğŸ©¸ **Placental Abruption**: Higher incidence","âš¡ **Fetal Distress**: Non-reassuring fetal status","ğŸ”„ **Growth Cessation**: Complete growth arrest","ğŸ§  **Fetal Acidosis**: Metabolic acidemia"]},{title:"Intrapartum Complications",points:["ğŸ“‰ **Fetal Distress**: Abnormal fetal heart rate patterns","ğŸ©¸ **Cord Compression**: Variable decelerations","ğŸŒ¡ï¸ **Fetal Hyperthermia**: Poor temperature regulation","ğŸ’š **Meconium Aspiration**: Thick meconium passage","âš¡ **Cord Prolapse**: Higher risk with oligohydramnios","ğŸ”ª **Operative Delivery**: Increased cesarean rate"]},{title:"Immediate Neonatal Complications",points:["ğŸ« **Respiratory Distress**: RDS, pneumonia","ğŸ§  **HIE**: Hypoxic-ischemic encephalopathy","ğŸ¯ **Hypoglycemia**: Low blood glucose","ğŸŒ¡ï¸ **Hypothermia**: Temperature instability","ğŸ©¸ **Polycythemia**: Increased hematocrit","ğŸ«˜ **Renal Failure**: Acute kidney injury"]},{title:"Neonatal Intensive Care Complications",points:["ğŸ« **Ventilator Dependence**: Prolonged respiratory support","ğŸ¼ **Feeding Intolerance**: NEC, feeding difficulties","ğŸ¦  **Nosocomial Infections**: Hospital-acquired infections","ğŸ§  **IVH**: Intraventricular hemorrhage","ğŸ‘ï¸ **ROP**: Retinopathy of prematurity","ğŸ¦´ **Osteopenia**: Metabolic bone disease"]},{title:"Developmental Complications",points:["ğŸ§  **Cerebral Palsy**: Motor dysfunction","ğŸ“š **Learning Disabilities**: Cognitive impairment","ğŸ‘ï¸ **Visual Impairment**: Cortical blindness, ROP sequelae","ğŸ‘‚ **Hearing Loss**: Sensorineural hearing loss","ğŸ’ª **Motor Delays**: Gross and fine motor","ğŸ—£ï¸ **Speech Delays**: Language development"]},{title:"Maternal Complications",points:["ğŸ§  **Psychological Impact**: Anxiety, depression","ğŸ¤° **Pregnancy Complications**: Preeclampsia, abruption","ğŸ”ª **Operative Delivery**: Increased surgical morbidity","ğŸ’” **Grief**: Perinatal loss, NICU admission","ğŸ‘¥ **Social Impact**: Family stress, financial burden","ğŸ”„ **Recurrence**: Risk in subsequent pregnancies"]}]}],d=()=>[{title:"Prevention Strategies for Fetal Growth Restriction",subsections:[{title:"Preconception Prevention",points:["ğŸ½ï¸ **Nutritional Optimization**: Adequate BMI, micronutrients","ğŸ’Š **Folic Acid**: 400-800 mcg daily","ğŸš« **Smoking Cessation**: Complete cessation before conception","ğŸ· **Alcohol Avoidance**: Eliminate alcohol consumption","ğŸ’Š **Medication Review**: Optimize medications for pregnancy","ğŸ©º **Medical Optimization**: Control chronic diseases"]},{title:"Primary Prevention",points:["ğŸ’Š **Low-dose Aspirin**: 75-150mg daily if high risk","ğŸ½ï¸ **Adequate Nutrition**: Balanced diet, appropriate weight gain","ğŸš« **Substance Avoidance**: Tobacco, alcohol, illicit drugs","ğŸ’§ **Infection Prevention**: Vaccines, hygiene measures","ğŸ›¡ï¸ **Environmental**: Avoid toxins, radiation","ğŸ”„ **Regular Antenatal Care**: Early and frequent visits"]},{title:"Secondary Prevention",points:["ğŸ“Š **Risk Assessment**: Identify high-risk pregnancies","ğŸ” **Enhanced Screening**: Serial growth scans","ğŸ’Š **Targeted Interventions**: Treat underlying conditions","ğŸ“± **Intensive Monitoring**: Increased surveillance","ğŸ¯ **Early Detection**: Prompt recognition of FGR","âš¡ **Timely Intervention**: Appropriate management"]},{title:"Tertiary Prevention",points:["ğŸ¥ **Optimal Delivery**: Timing and mode of delivery","ğŸ‘¶ **Neonatal Care**: Specialized newborn management","ğŸ”„ **Long-term Follow-up**: Developmental monitoring","ğŸ“š **Early Intervention**: Developmental support services","ğŸ‘¥ **Family Support**: Psychological and social support","ğŸ¯ **Recurrence Prevention**: Planning subsequent pregnancies"]},{title:"High-Risk Population Strategies",points:["ğŸ“Š **Risk Stratification**: Identify highest risk groups","ğŸ¯ **Targeted Screening**: Focused prevention programs","ğŸ’Š **Prophylactic Interventions**: Aspirin, nutritional support","ğŸ“š **Education Programs**: Community health education","ğŸ¥ **Specialized Clinics**: High-risk pregnancy units","ğŸ”„ **Quality Improvement**: Systematic prevention programs"]},{title:"Public Health Measures",points:["ğŸš« **Tobacco Control**: Population-level smoking reduction","ğŸ½ï¸ **Nutrition Programs**: Food security, supplementation","ğŸ¥ **Healthcare Access**: Improve antenatal care availability","ğŸ“š **Education**: Public awareness campaigns","ğŸ’° **Economic Support**: Address poverty and inequality","ğŸŒ **Environmental Health**: Reduce pollution exposure"]}]}],u=()=>[{title:"Kenya-Specific Considerations for FGR",subsections:[{title:"Epidemiology in Kenya",points:["ğŸ“Š **Prevalence**: 8-15% of pregnancies affected","ğŸŒ¾ **Rural vs Urban**: Higher rates in rural areas","ğŸ’° **Socioeconomic**: Strong association with poverty","ğŸ½ï¸ **Malnutrition**: Maternal undernutrition common","ğŸ¦  **Infections**: Malaria, HIV, TB as major causes","ğŸ‘© **Maternal Age**: Teenage pregnancies at higher risk"]},{title:"Specific Risk Factors",points:["ğŸ¦  **Malaria**: Major preventable cause of FGR","ğŸ”´ **HIV Infection**: Direct and indirect effects","ğŸ« **Tuberculosis**: Active and latent TB","ğŸ½ï¸ **Food Insecurity**: Chronic malnutrition","ğŸ’§ **Water/Sanitation**: Poor hygiene, infections","ğŸŒ¡ï¸ **Climate Change**: Extreme weather events"]},{title:"Healthcare System Challenges",points:["ğŸ¥ **Limited Resources**: Shortage of ultrasound machines","ğŸ‘¨â€âš•ï¸ **Human Resources**: Insufficient trained sonographers","ğŸš— **Geographic Access**: Distance to health facilities","ğŸ’° **Financial Barriers**: Cost of investigations","ğŸ“Š **Data Systems**: Poor record keeping","ğŸ”„ **Referral Systems**: Weak referral mechanisms"]},{title:"Adapted Management Approaches",points:["ğŸ“ **Clinical Assessment**: Emphasis on fundal height measurement","ğŸ¤² **Physical Examination**: Skilled clinical evaluation","ğŸ“Š **Risk Scoring**: Simple risk assessment tools","ğŸ’Š **Empirical Treatment**: Treat likely causes","ğŸ¥ **Hub and Spoke**: Centralized specialist services","ğŸ“± **Mobile Health**: Use of technology for monitoring"]},{title:"Prevention Strategies",points:["ğŸ¦  **Malaria Prevention**: IPTp, LLINs, effective case management","ğŸ½ï¸ **Nutritional Support**: Supplementation programs","ğŸ’Š **Micronutrients**: Iron, folic acid, vitamin A","ğŸ›¡ï¸ **Infection Control**: HIV prevention, TB screening","ğŸ“š **Health Education**: Community awareness programs","ğŸ‘¥ **Community Health**: CHW involvement"]},{title:"Quality Improvement Initiatives",points:["ğŸ“Š **Surveillance Systems**: Improve data collection","ğŸ“š **Training Programs**: Capacity building","ğŸ”„ **Quality Audits**: Regular case reviews","ğŸ¯ **Guidelines**: Locally adapted protocols","ğŸ’° **Resource Allocation**: Priority setting","ğŸ¤ **Partnerships**: Collaboration with NGOs, development partners"]},{title:"Research Priorities",points:["ğŸ“Š **Epidemiological Studies**: Local prevalence and causes","ğŸ§¬ **Genetic Factors**: Population-specific genetic variants","ğŸ¦  **Infectious Causes**: Malaria, HIV, TB interactions","ğŸ½ï¸ **Nutritional Interventions**: Effective supplementation","ğŸ“± **Technology Solutions**: Mobile health applications","ğŸ’° **Cost-Effectiveness**: Economic evaluation of interventions"]}]}];export{g as getFetalGrowthRestrictionContent};
